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The Independent Hem/Onc News Source @OncologyTimes OncologyTimesNews disease-specific, and progression-free survivals of 49, 74, and 48 percent, respectively� Moreover, two-thirds of patients had Swallowing Performance Status Scale (SPSS) scores of ≤5, indicating that a gastrostomy tube was not required to maintain nutrition� There are multiple considerations, therefore, when treating a patient with larynx cancer� Initial steps include staging and ascertaining whether a curative, organ-preservation approach is appropriate� For many patients this will consist of concurrent chemoradiotherapy of cisplatin (100 mg/m 2 ) and single-daily fractionated radiotherapy� For almost two decades we have used an FHX-based regimen in these patients with appreciable success including those with large volume disease� Current efforts are focused on further stratifying patients based on molecular characteristics of the tumor that will allow greater patient selection for chemoradiotherapy and even guide which agents are likely to be most effective� 
Biomarkers Did Not Correlate
At the time the study was planned the researchers noted a high frequency of BRAF and KRAS mutations in low-grade serous ovarian tumors, and hypothesized that MAPK inhibition would be a potentially active intervention� But among the 16 patients identified with tumors with BRAF or KRAS mutations, only two had responses� "Our results suggest that selumetinib is an active agent, but not necessarily because of BRAF or KRAS mutational activation per se," the authors concluded�
In an interview, Gershenson said that one reason for the lack of correlation could be biomarker instability� Among the 52 patients, specimens were available for only 40, mutational analysis was done in 34, and in 28 of those the tissue was from the primary therapy and not from the recurrent tumor� "The question arises, are these biomarkers stable over time or do they change, so that what you find in the primary tumor may not be what you find in the recurrent tumor," he said�
He noted that an unpublished study conducted with a group in Vancouver suggests that biomarkers may indeed change over time� "We don't really understand the circuitry in these signal transduction pathways nearly as well as we think we do� And as we do these targeted therapy trials, we are learning that just because you have a mutation, that does not translate into a response�"
The study's first author, John H� Farley, MD, COL (Ret), Professor in the Division of Gynecologic Oncology at Creighton University School of Medicine St� Joseph's Hospital and Medical Center in Phoenix, explained in an interview that the MAP kinase pathway is very intricate and that some tumors may be going around the RAS/RAF mutational pathway� "It appears that the MAP kinase pathway in these tumors is activated in a different way, other than KRAS and BRAF mutations� If you look at response to therapy as an expression of phosphorylated ERK downstream, there does potentially appear to be a correlation to response�"
He and his coauthors called this finding "potentially provocative in view of the I was interested to read the article in the January 10 issue about specific strategies that can mobilize millions of stem cells� Strategies mentioned included (1) avoid radiation, multiple cycles of chemotherapy, and myelotoxic drugs, (2) collect early in treatment, (3) use higher doses of filgrastim or pegfilgrastim, (4) utilize chemomobilization plus colony-stimulating factor, and (5) use plerixafor to augment filgrastim�
The diseases noted were lymphoma and multiple myeloma� These are different diseases with different treatment strategies, and the opportunity to mobilize after induction will depend on the treatment used during induction� The definition of "early treatment" is therefore likely meant as early during treatment in cycles 1 or 2 of treatment� Can this safely be realized in lymphoma and multiple myeloma?
In the early '90s I was heavily involved in the definition of optimal timing of leukapheresis for collection of hematopoietic progenitor cells� At the time we performed a study and mobilized by chemotherapy and granulocyte colonystimulating factor (G-CSF) and assessed the opportunity to do so in cycle one and four of the treatment� For collection, white blood cell count and circulating CD34+ cells were measured and colony-forming cells and longterm culture initiating cells were assessed in cultures� 1,2 The results of these studies showed that mobilization of CD34+ cells, colony-forming cells, and longterm culture-initiating cells was far better during the first than the fourth cycle of chemotherapy and G-CSF� Moreover these studies showed that the mobilizing capacity rapidly decreased and was far less after one treatment of just four cycles of therapy�
The concern of collection in the first cycle of chemotherapy is that tumor cells may also be mobilized� It has been shown that myeloma cells do not mobilize, but it has not been extensively examined early during treatment; in lymphoma it appears that circulating lymphoma cells are rapidly eliminated by anti-CD20 if anti-CD20 is part of the therapy� To circumvent the high drug costs of plerixafor, use of leukapheresis should be considered during the first or second cycle of therapy�
The question then arises when to start leukapheresis; we kept as optimal when the white blood cell count increased from nadir to 4 × 10e9/L and performed leukapheresis on that particular day; this strategy made it possible to collect more than 2 × 10e6 CD34+ cells/kg during one 12-liter leukapheresis in most patients� Moreover it appeared predictable that this would occur on day 11 or 12 of cycle one when G-CSF was started on day 2 of the cycle� Our data are consistent with the recommendations made in the study reported in the article� With CHOP-R being the standard treatment for patients with diffuse large B-cell lymphoma, the addition of G-CSF makes it possible to collect during cycle one on day 11 or 12 when the white blood cell count increases to 4 × 10e9/L� Moreover it is likely that by day 11 and 12 of the first cycle that lymphoma cells are no longer circulating in the peripheral blood� For early collection of peripheral blood progenitor cells in multiple myeloma, cyclophosphamide might need to be included in the first cycle(s) of treatment and G-CSF� However as not all agents are given on day 1 of treatment, research will need to show when the white blood cell count rises to 4 × 10e9/L� The question remains whether there is a role in this regard of anti-CD20 in multiple myeloma; although it has not been examined in first line therapy, use of anti-CD20 in the 20 percent of multiple myeloma patients who do express CD20 might have another rationale-to eliminate potentially circulating multiple myeloma cells� Letters regulatory trends and recommendations for clinical trial design that are moving in a more restrictive direction� The decision to allow patients with and without BRAF or KRAS mutational activation proved to be appropriate," Farley said� "Unless the evidence for restricting eligible patients is compelling, trial designs must allow hypotheses to be adequately tested clinically�"
Low Toxicity Profile
In the trial-an abstract of which was reported at last year's American Association for Cancer Research Annual Meeting (OT, 5/10/12 issue)-there were no treatment-related deaths� Grade 4 toxicities were cardiac (one), pain (one), and pulmonary events (one)� Grade 3 toxicities that occurred in more than one patient were gastrointestinal (13), dermatological (nine), metabolic (seven), fatigue (six), anemia (four), pain (four), constitutional (three), and cardiac events (two)� The patients were heavily pretreated: 30 (58%) had received three or more previous chemotherapeutic regimens; and 82 (65%) had previous regimens that contained platinum� A trial of another MEK inhibitor is being planned, Gershenson said, noting that he will lead a Phase II/III international trial of trametinib (GSK1120212), which has a longer half-life than selumetinib� The trial, which he said has been approved by the National Cancer Institute's Gynecologic Cancer Steering Committee and will take place in the U�S� and U�K�, will directly compare trametinib with the attending physicians' choice of hormonal and/or cytotoxic therapy� The trial with 250 patients is expected to begin this summer� The study will analyze both recurrent and primary tumor tissue and will also require mandatory biopsy prior to starting therapy, he said� "We think that will give us a better chance of correlating the outcome to the biomarkers�" Debulking Not Addressed An editorial accompanying the study ("Towards Individualised Treatment," Lancet Oncology 2013;14:101-102), noted that a strength of the study was the mandatory reference pathology of recurrent disease to exclude patients with progression to high-grade disease who would have been likely to benefit from chemotherapy, and recurrent borderline ovarian tumors that have excellent prognosis with salvage surgery alone� A possible drawback, though, was that the issue of debulking surgery was not addressed� Elaborating in an email exchange, Sven Mahner, MD, Chief Consultant in the Department of Gynecology at University Medical Center HamburgEppendorf in Germany, said that since a low-grade ovarian carcinoma can often be repeatedly surgically removed, it would be interesting to first operate on these patients and then treat them with selumetinib�
In response, Farley said that the main outcome of the study was progression-free survival and that debulking surgery would not have affected that endpoint-"Our patients were heavily pretreated, some with five previous treatments, and the time for surgical treatment had passed�"
Mahner was also asked about the lack of correlation of biomarkers and outcomes� He said he agreed with Gershenson that degradation of specimens can be a problem-"However, this also holds true for the specimens that biomarkers have originally been established on� A clinically useful biomarker should therefore be somewhat independent from this process-like hormone-receptor status or HER2 expression in breast cancer, for example�" Biomarker-driven studies will remain an important tool in future development of many substances, he said, "and the selumetinib study is a good example, that a good biological hypothesis and targeted therapy can be successful despite a nonindicative marker�" O T
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